Literature DB >> 21576339

Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells.

David M White1, Sabine Pellett, Mark A Jensen, William H Tepp, Eric A Johnson, Barry G W Arnason.   

Abstract

The clostridial botulinum neurotoxins (BoNTs) are the most potent protein toxins known. The carboxyl-terminal fragment of the toxin heavy chain (Hc) has been intensively investigated as a BoNT vaccine immunogen. We sought to determine whether targeting Hc to antigen-presenting cells (APCs) could accelerate the immune responses to vaccination with BoNT serotype A (BoNT/A) Hc. To test this hypothesis, we targeted Hc to the Fc receptors for IgG (FcγRs) expressed by dendritic cells (DCs) and other APCs. Hc was expressed as a fusion protein with a recombinant ligand for human FcγRs (R4) to produce HcR4 or a similar ligand for murine FcγRs to produce HcmR4. HcR4, HcmR4, and Hc were produced as secreted proteins using baculovirus-mediated expression in SF9 insect cells. In vitro receptor binding assays showed that HcR4 effectively targets Hc to all classes of FcγRs. APCs loaded with HcR4 or HcmR4 are substantially more effective at stimulating Hc-reactive T cells than APCs loaded with nontargeted Hc. Mice immunized with a single dose of HcmR4 or HcR4 had earlier and markedly higher Hc-reactive antibody titers than mice immunized with nontargeted Hc. These results extend to BoNT neutralizing antibody titers, which are substantially higher in mice immunized with HcmR4 than in mice immunized with Hc. Our results demonstrate that targeting Hc to FcγRs augments the pace and magnitude of immune responses to Hc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576339      PMCID: PMC3147575          DOI: 10.1128/IAI.00166-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Purification of Clostridium botulinum type A neurotoxin.

Authors:  C J Malizio; M C Goodnough; E A Johnson
Journal:  Methods Mol Biol       Date:  2000

2.  Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia.

Authors:  D S Southam; M Dolovich; P M O'Byrne; M D Inman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-04       Impact factor: 5.464

Review 3.  Antigen presentation and T cell stimulation by dendritic cells.

Authors:  Pierre Guermonprez; Jenny Valladeau; Laurence Zitvogel; Clotilde Théry; Sebastian Amigorena
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 4.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

5.  C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine.

Authors:  Jae-Chul Lee; Hyun-Jung Hwang; Yoshihiko Sakaguchi; Yumiko Yamamoto; Hideyuki Arimitsu; Takao Tsuji; Toshihiro Watanabe; Tohru Ohyama; Tomofusa Tsuchiya; Keiji Oguma
Journal:  Microbiol Immunol       Date:  2007       Impact factor: 1.955

6.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 7.  Botulinum toxin as a biological weapon: medical and public health management.

Authors:  S S Arnon; R Schechter; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; J Hauer; M Layton; S Lillibridge; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; D L Swerdlow; K Tonat
Journal:  JAMA       Date:  2001-02-28       Impact factor: 56.272

8.  Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system.

Authors:  J S Lee; P Pushko; M D Parker; M T Dertzbaugh; L A Smith; J F Smith
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

9.  Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice.

Authors:  T Keler; P M Guyre; L A Vitale; K Sundarapandiyan; J G van De Winkel; Y M Deo; R F Graziano
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

10.  Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors.

Authors:  D M White; M A Jensen; X Shi; B G Arnason
Journal:  Protein Expr Purif       Date:  2001-04       Impact factor: 1.650

View more
  8 in total

1.  Oral vaccination with an adenovirus-vectored vaccine protects against botulism.

Authors:  Shan Chen; Qingfu Xu; Mingtao Zeng
Journal:  Vaccine       Date:  2013-01-04       Impact factor: 3.641

2.  Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.

Authors:  Constantine Bitsaktsis; Bibiana V Iglesias; Ying Li; Jesus Colino; Clifford M Snapper; Susan K Hollingshead; Giang Pham; Diane R Gosselin; Edmund J Gosselin
Journal:  Infect Immun       Date:  2011-12-12       Impact factor: 3.441

3.  DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: examples of the botulinum toxins types A, B, and E.

Authors:  Aurore Burgain; Alice Rochard; Capucine Trollet; Christelle Mazuet; Michel R Popoff; Virginie Escriou; Daniel Scherman; Pascal Bigey
Journal:  Hum Vaccin Immunother       Date:  2013-07-22       Impact factor: 3.452

4.  Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.

Authors:  Andrew W Hudacek; Fetweh H Al-Saleem; Mallory Willet; Travis Eisemann; Jeffrey A Mattis; Lance L Simpson; Matthias J Schnell
Journal:  Mol Ther Methods Clin Dev       Date:  2014-10-01       Impact factor: 6.698

Review 5.  The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.

Authors:  Rachael S Felberbaum
Journal:  Biotechnol J       Date:  2015-03-20       Impact factor: 4.677

6.  Multiple mechanisms mediate enhanced immunity generated by mAb-inactivated F. tularensis immunogen.

Authors:  Bibiana V Iglesias; Constantine Bitsaktsis; Giang Pham; James R Drake; Karsten R O Hazlett; Kristen Porter; Edmund J Gosselin
Journal:  Immunol Cell Biol       Date:  2012-12-18       Impact factor: 5.126

7.  A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.

Authors:  Xue Chen; Hongyang Liu; Ting Zhang; Yanchun Liu; Xixiu Xie; Zhirong Wang; Xuemei Xu
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

Review 8.  Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches.

Authors:  Christine Rasetti-Escargueil; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2019-09-12       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.